# Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

> **NCT02078648** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stemline Therapeutics, Inc.** · enrollment: 74 (actual)

## Conditions studied

- Adult Brain Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
- **DRUG:** Bevacizumab
- **DRUG:** SL-701 + GM-CSF
- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT02078648
- **Lead sponsor:** Stemline Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2017-09-01
- **Final completion:** 2018-01-22
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078648, "Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02078648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*